Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 14.05.2021 16:25
Latest

8.50 NOK

Change

0.04

Change (%)

0.47

Share information

IR contact

News

Reports

Governance

HBC 1
LATEST REPORT

Annual Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Annual report 2020
All reports
16:9
NEXT UP

Financial calendar

Quarterly Report Q1
21.05.2021

Half-yearly Report
27.08.2021

Quarterly Report Q3
05.11.2021

Quarterly Report Q4
04.02.2022

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Stock exchange notices

View all notices

GLOBAL INNOVATION PARTNERSHIP WITH CATALENT TO DEVELOP DELAYED-RELEASE FORMULATION OF OMEGO FISH OIL

12.05.2021

COMPLETED ANNUAL GENERAL MEETING

23.04.2021

IMCD AND HBC EXTEND INTERNATIONAL AGREEMENT TO INCLUDE EUROPE

15.04.2021

Hofseth BioCare ASA: NOTICE OF ANNUAL GENERAL MEETING 2021

05.04.2021

NESTLE-OWNED GARDEN OF LIFE TO LAUNCH NEW PRODUCTS WITH PROGO® IN US RETAIL & ONLINE MARKETS

31.03.2021

Contact investor relations

James Berger
James Berger
Chief Commercial Officer
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Head of Medical R&D
+44 7968 195497 cc@hofsethbiocare.no